TLP
ABBV icon

Trinity Legacy Partners’s AbbVie ABBV Stock Holding History

Trinity Legacy Partners’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,600
Closed -$3K – 104
2021
Q2 		$3K Buy
2,600
+900
+53% +$101K ﹤0.01% 104
2021
Q1 		$6K Buy
1,700
+900
+113% +$96.3K ﹤0.01% 89
2020
Q4 		$5K Buy
+800
New +$76.9K ﹤0.01% 83

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Trinity Legacy Partners's ABBV Position: Q1 2025 in Review

Trinity Legacy Partners sold out of AbbVie (ABBV) in Q1 2025, closing a stake of 1,224 shares — an estimated $218K sold.

Trinity Legacy Partners first reported a position in ABBV in Q3 2019 and held it in 22 quarters. The position peaked at $5.44M in Q1 2022. 3,819 funds tracked by Wall St. Rank hold ABBV as of Q1 2025.

  • Trinity Legacy Partners reported no remaining AbbVie position as of Q1 2025 after selling out during the quarter.
  • Trinity Legacy Partners sold 1,224 AbbVie shares in Q1 2025, an estimated $218K.
  • Trinity Legacy Partners first reported a position in AbbVie in Q3 2019 and held it in 22 quarters.
  • Trinity Legacy Partners's AbbVie position peaked at $5.44M in Q1 2022.
  • 3,819 funds tracked by Wall St. Rank held AbbVie as of Q1 2025.

Based on Trinity Legacy Partners's 13F filing for Q1 2025, filed 14 May 2025.